Related Experiment Video
Updated: Jul 20, 2025

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Regulatory Oversight of Cell and Gene Therapy Products in Malaysia
Evelyn Yun Xi Loh1, Azizah Ab Ghani2, Rosilawati Ahmad3
1Biologics Section, Centre of Product and Cosmetic Evaluation, National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia, Selangor, Malaysia.
Abstract:
The National Pharmaceutical Regulatory Agency (NPRA) is the agency responsible for the registration of pharmaceutical, natural, and health supplement products and notification of cosmetic products that are marketed in Malaysia. The implementation of regulatory oversight of the different types of product was in a progressive manner, with the latest addition to be regulated being the cell and gene therapy products (CGTPs), beginning January 1, 2021. CGTP can be classified as low risk (that does not require registration) or high risk (that needs to be registered). Generally, the regulation of high-risk CGTP is similar to other biological products. This chapter describes the chronology of the CGTP framework, classification of CGTP, how CGTPs fit into the current registration pathways and registration procedure, dossier requirements, and what is the current status and future direction of CGTP in Malaysia.
Related Concept Videos
Drug Regulation
Gene Therapy
Drug Control Governance: Regulatory Bodies and Their Impact
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
iPS Cell Differentiation
Regulation of Hematopoietic Stem Cells

